Kalvista pharma CMO Audhya sells $38k in shares

Chief Medical (TASE:BLWV) Officer of KalVista Pharmaceuticals (NASDAQ:KALV), Paul K. Audhya, sold 2,939 shares of common stock on August 18, 2025, at a price of $13.187 per share, totaling $38,756. The sale comes amid KALV’s strong year-to-date performance of 57.5%, with the stock currently trading near $12.81. InvestingPro analysis shows analysts maintain a strong buy consensus with price targets ranging from $20 to $40.

On August 17, Audhya also exercised options to acquire 6,446 shares of KalVista Pharmaceuticals’ common stock. Additionally, the report details the exercise of options to acquire 2,418 and 4,028 restricted stock units. While the company maintains a strong liquidity position with a current ratio of 5.35, InvestingPro subscribers can access detailed insider trading patterns and 8 additional key financial insights about KALV’s current market position.

In other recent news, KalVista Pharmaceuticals, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of sebetralstat, an oral treatment for hereditary angioedema (HAE) attacks. If approved by the European Commission, it would become the first oral on-demand treatment for HAE in the European Union. Additionally, the UK’s Medicines and Healthcare products Regulatory Agency has granted marketing authorization for EKTERLY (sebetralstat), marking it as the first oral treatment for HAE in the UK, with market exclusivity for up to 10 years. Following this UK approval, JMP Securities reiterated its Market Outperform rating and $27.00 price target on KalVista Pharmaceuticals, highlighting the potential of the on-demand HAE market. The firm also noted the market’s stabilization at over $600 million in annual sales. Meanwhile, Metagenomi, Inc. has appointed biotech veteran Laurence Reid to its Board of Directors, bringing 30 years of industry experience. Reid currently holds board positions at multiple biotechnology companies, including KalVista Pharmaceuticals. These developments reflect ongoing advancements and strategic appointments within the biotechnology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.